AIM
VNDA icon

Alambic Investment Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Alambic Investment Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-11,706
Closed -$269K – 378
2018
Q3 		$269K Sell
11,706
-113,440
-91% -$2.32M 0.21% 169
2018
Q2 		$2.38M Sell
125,146
-59,754
-32% -$999K 0.65% 40
2018
Q1 		$3.12M Buy
+184,900
New +$3.09M 0.43% 74

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Alambic Investment Management's VNDA Position: Q4 2018 in Review

Alambic Investment Management sold out of Vanda Pharmaceuticals (VNDA) in Q4 2018, closing a stake of 11,706 shares — an estimated $269K sold.

Alambic Investment Management first reported a position in VNDA in Q1 2018 and held it in 3 quarters. The position peaked at $3.12M in Q1 2018. 186 funds tracked by Wall St. Rank hold VNDA as of Q4 2018.

  • Alambic Investment Management reported no remaining Vanda Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Alambic Investment Management sold 11,706 Vanda Pharmaceuticals shares in Q4 2018, an estimated $269K.
  • Alambic Investment Management first reported a position in Vanda Pharmaceuticals in Q1 2018 and held it in 3 quarters.
  • Alambic Investment Management's Vanda Pharmaceuticals position peaked at $3.12M in Q1 2018.
  • 186 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2018.

Based on Alambic Investment Management's 13F filing for Q4 2018, filed 12 Feb 2019.